CHAPEL HILL, N.C. — A $40 million payday from drug development partner AstraZeneca means bonuses for some Pozen executives and “certain” non-executive employees.
In a filing with the Securities and Exchange Commission, Pozen (Nasdaq: POZN) disclosed the payment of $535,150 in bonuses based on the AstraZeneca deal to jointly develop a pain reliever.
Kristina Adomonis, senior vice president of business development, gets the biggest bonus: $180,400.
Chief Executive Officer John Plachetka receives $169.950.
Also getting bonuses were Chief Financial Officer William Hodges ($16,500) and Marshall Reese, executive vice president for product development.
Other bonuses will be distributed at Plachetka’s discretion, Pozen said.